European Network for the Study of Adrenal Tumors (ENS@T) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2018
NCT03583710
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

European Network for the Study of Adrenal Tumors (ENS@T)

Active Ingredients

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

mitotane (lysodren) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenal Cortex Neoplasms (Phase 3)

Adrenocortical Carcinoma (Phase 3)

Carcinoma (Phase 3)

Recurrence (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3